Exelixis
EXEL
#1323
Rank
$16.97 B
Marketcap
$69.57
Share price
1.25%
Change (1 day)
68.00%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.28

According to Exelixis's latest financial reports the company's current EPS (TTM) is $3.46. In 2022 the company made an earnings per share (EPS) of $0.57 a decrease over its 2021 EPS that were of $0.74.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.28-50.3%
2022$0.57-22.97%
2021$0.74100%
2020$0.37-65.09%
2019$1.06-53.91%
2018$2.30333.96%
2017$0.53-260.61%
2016-$0.33-58.75%
2015-$0.80-42.45%
2014-$1.395.3%
2013-$1.3243.48%
2012-$0.92-264.29%
2011$0.56-165.88%
2010-$0.85-32.54%
2009-$1.26-17.65%
2008-$1.5375.86%
2007-$0.87-25.64%
2006-$1.178.33%
2005-$1.08-42.86%
2004-$1.8930.34%
2003-$1.45-5.23%
2002-$1.53-0.65%
2001-$1.54-51.88%
2000-$3.20

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
$6.68 93.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
$0.76-78.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
$16.22 368.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
$1.90-45.00%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
$0.99-71.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
$4.52 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
$2.88-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-$14.22-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-$0.84-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA